Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CAT | P04040 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19886697 | 0.88 | FPR2 (0.33) | HDAC1 | |
| SCHEMBL18089739 | 0.88 | — | — | |
| SCHEMBL19886693 | 0.86 | CAT (0.32) | CAT | |
| SCHEMBL18089738 | 0.85 | CAT (0.46) | CAT | |
| SCHEMBL18089423 | 0.81 | ALDH1A1 (0.34) | POLB | |
| SCHEMBL18089740 | 0.81 | ALDH1A1 (0.34) | POLB | |
| SCHEMBL19886698 | 0.77 | P2RX7 (0.36) | POLB | |
| SCHEMBL18662404 | 0.76 | CA12 (0.33) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17286497 | 0.76 | CA12 (0.33) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21503787 | 0.76 | CA2 (0.41) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211037-A1 | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES IN ANTIMICROBIAL TREATMENT | REMPEX PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180051041-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC | 2018-02-22 | — | — | US | disclosed |
| WO-2016149393-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051041-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BTD, BCL6 | CA12 258/4885CA1 1317/4885CA2 287/4885 |
| US-20190211037-A1 | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES IN ANTIMICROBIAL TREATMENT | BTD, BCL6B, BPGM | CA12 758/4885CA1 3404/4885CA2 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.